SYNAPS Dx focuses on the research, development and commercialization of diagnostics for neurodegenerative disorders, including Alzheimer’s Disease. Its lead product, DISCERN, is described as the first autopsy-validated, highly accurate, minimally invasive test that distinguishes AD from other forms of dementia. The test is supported by three SDx AD biomarkers tied to PKC‑Epsilon molecular pathways and validated using NIH ‘gold standard’ dementia-in-life and autopsy confirmation. Clinical data show DISCERN has 95% sensitivity and 95% specificity. The company operates a CLIA‑certified laboratory qualified for high‑complexity clinical testing. Management says proceeds from the recent financing will be used to scale up production and meet rising market demand amid increased payer and drug‑development focus on accurate early diagnosis. The company cites roughly 500,000 new U.S. dementia cases per year and about 2 million patients in years 0–3 as drivers of near‑term demand.

Total raised

$10M

Funding rounds

1

Latest round

Series A

Latest activity

Oct 2021